glp-1 weight loss drugs news today With FDA approval of Wegovy pill, new era of oral begins Amazon expands access to GLP-1

Multiple studies highlight its potential applications in prevention

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

Learn what drives costs and how coverage impacts spending.

Comprehensive Metabolic Health & Fat Metabolism Support

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk